During the COVID-19 crisis, managed care professionals are facing unique challenges to deliver patient care. This resource center is designed to aggregate timely information for AMCP members and stakeholders.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
From News & Views: AMCP News & Views recently caught up with John Peterkins, vice president of market access at Optinose to learn about his company and gain insights on becoming an AMCP Corporate Member.
AMCP, Alliance, and Thirteen Fellow Healthcare Education Organizations announced today the formation of its new CEHp Partners’ Council. Through this formal collaboration, the CEHp Partners’ Council will cultivate a community of peer educational associations who strive to improve continuing education within and across the health professions to meet the ever-changing needs of health care providers and their patients.
Health care expert Fred Goldstein of AMCP Podcast Powered by PopHealth Week sits down with Dr. April Armstrong to discuss psoriasis, a chronic and systemic inflammatory skin disease affecting children as well as adults and the tremendous impact on their physical and mental impact on quality of life.
